43 results about "Specific igg" patented technology

The present application provides an RNA encoding a varicella-zoster (VZV) glycoprotein E (gE) or a variant thereof, the RNA comprising a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the nucleotide sequence represented by any one of SEQ ID NO: 11-18. The eight mRNAs provided by the invention can translate in cells, the expression level of the generated VZV gE protein is high, and the mRNAs can induce a mouse to generate a high-titer gE specific IgG antibody in a manner of intramuscular injection into the body of the mouse through a preparation formed by encapsulating the lipidosome nanoparticles.

The invention discloses a vaccine composition and a preparation method thereof, the vaccine composition comprises a first component and a second component, the first component is a recombinant protein antigen, the second component is an oil-in-water composite adjuvant, and the oil-in-water composite adjuvant comprises a water phase, an oil phase, an emulsifier, a Toll-like receptor stimulant and / or an STING stimulant. The vaccine composition provided by the invention can stimulate a body to generate a high-level specific IgG antibody and a neutralizing antibody, and has a good cellular immune effect at the same time. The second component provided by the invention is simple in preparation process, low in cost, stable in dosage form, easy to store and good in immune effect, and has a wide application prospect in vaccine or drug development.

The present invention relates to the technical field of nanomaterials for vaccines, and particularly relates to a sepiolite in-situ grown nanozyme, a preparation method thereof and an application thereof. The preparation method is to mix ferric chloride, ethylene glycol and sodium acetate to form a suspension, and then mix sepiolite with the suspension, and react at a temperature of 180-200 °C to obtain a black precipitate. After washing and drying, sepiolite in-situ grown nanozyme is obtained. The sepiolite nanozyme realizes the in-situ growth of iron-based nanozyme on the surface of sepiolite rod-like nanostructures under hydrothermal conditions, significantly enhancing the peroxidase activity. After Sep@IONzyme is connected with inactivated influenza virus, the complex forms an appropriate positive charge distribution, enhancing the adhesion ability of the antigen to nasal mucosa. Immunizing mice with it as a nasal drop vaccine significantly improves the levels of respiratory mucosal specific sIgA antibody and serum specific IgG antibody, and can completely protect against the lethal attack of influenza virus.

The invention discloses a bivalent subunit vaccine for preventing infection of haemophilus parasuis and porcine circovirus type 2. A core antigen combination of the vaccine comprises at least one antigen protein from haemophilus parasuis, and the antigen protein is selected from Ferrin, OppA and Hem-SAP and is combined with a porcine circovirus type 2 Cap protein. Wherein the NCBI (National Center of Biotechnology Information) login number of the Ferrin, the NCBI login number of the OppA and the NCBI login number of the Hem-SAP are WP160414389.1, ACL32731.1 and WP035493594.1 respectively. The antigen protein is subjected to codon optimization, is expressed and purified through a prokaryotic expression system, and is emulsified with ISA201 or a Freund's adjuvant to prepare the vaccine. Animal experiments prove that the vaccine can excite high-level antigen specificity IgG, cell factors IFN-gamma and white IL-4 in an immune animal body, namely, specific Th1 and Th2 type immune responses are generated. The vaccine can generate an immune protection rate of up to 80% when attacked by a serum type 5 haemophilus parasuis virulent strain, and generates an effective antibody response to the porcine circovirus type 2. The vaccine provided by the invention has the advantages of definite components, good safety and strong immune protection force.

The present invention discloses a subunit vaccine against chicken infectious anemia virus, belonging to the technical field of animal disease vaccines. The present invention provides a subunit vaccine against chicken infectious anemia virus, and the active ingredient is a recombinant fusion protein of the B cell epitope of chicken infectious anemia virus VP1 protein and Salmonella typhimurium flagellin. The B cell epitope of chicken infectious anemia virus VP1 protein is obtained by connecting the B cell antigen epitopes contained in chicken infectious anemia virus VP1 protein through a linker peptide. The Salmonella typhimurium flagellin is obtained by deleting the hypervariable region of Salmonella typhimurium flagellin FliC. After the fusion expression protein of the present invention is administered to 1-day-old SPF chickens, it can induce the production of specific IgG antibodies, and after 28 days of immunization, the immunized chicken flock can resist the challenge of the virulent strain of chicken infectious anemia virus, and 70% of the challenged chicken flock is protected from disease. The present invention has great potential for clinical prevention and control of chicken infectious anemia virus infection.

The invention provides a novel vaccine adjuvant and application of the novel vaccine adjuvant in preparation of the vaccine adjuvant. The BCG-PSN and vaccine induced RBD specific IgG antibody and neutralizing antibody level are equivalent to those of an aluminum adjuvant, the BCG-PSN and vaccine induce Th1 biased T cell reaction, the induced T cell response level is obviously higher than that of the aluminum adjuvant, and K18-hACE2 mice are protected from being affected by Delta variant induced lung lesions. As a vaccine adjuvant, BCG-PSN has wide compatibility and safety, and has no toxic or side effect.

The invention relates to the technical field of detection kits, in particular to a milk specificity IgG antibody detection kit which comprises a detection kit body, a storage hole is formed in the bottom end of the detection kit body, the top end of the storage hole is communicated with a discharging cavity, and a feeding pipe fixedly penetrates through the middle of the side face of the detection kit body; the feeding pipe injects a sample solution into the discharging cavity, an extended cleaning mechanism is arranged on the inner wall of the storage hole, the top end of the discharging cavity is communicated with a detection cavity, and a cleaning mechanism, a sampling mechanism and a rotary detection mechanism are arranged on the inner wall of the detection cavity. The extended cleaning mechanism comprises a storage column arranged on the inner wall of the storage hole; the device can ensure that the cleaning scraping plate is continuously and tightly attached to the inner wall of the discharging cavity, the scraping efficiency is guaranteed, the cleaning quality is improved, the cleaning scraping plate can be stored and hidden after cleaning is completed, deformation caused by collision with a sampling rod during sampling is avoided, and the cleaning performance of the cleaning scraping plate is maintained.

The application discloses a HtsA-SLOdm fusion protein and application thereof in preparation of a group A streptococcus vaccine. The HtsA-SLOdm fusion protein is obtained by fusing and recombining a heme transport lipoprotein (HtsA) and a streptolysin protein containing a double-mutation site (SLOdm), can induce production of HtsA protein and SLOdm protein specific IgG antibodies in serum, has strong immunogenicity, can induce high-level IgG1 and IgG2a antibody titers, and the humoral immune response in inducing production of SLOdm protein specific IgG antibodies in serum is stronger than that of a single protein. In addition, the HtsA-SLOdm fusion protein can promote skin wound healing of mice, reduce bacterial content and inflammatory response at a skin infection site of the mice, accelerate wound healing, has almost no hemolytic activity, has high safety, and can be used for preparing a group A streptococcus vaccine.

Provided are an RSV F protein mutant, and a preparation method therefor and a use thereof. Provided is a mutant protein, the mutant protein being in the form of a monomer or a trimer, wherein the trimer is formed by three monomeric mutant proteins; the monomeric mutant protein is a fusion protein comprising a first polypeptide element derived from an RSV F protein and a trimerization domain element; in the first polypeptide element, a Pep27 fragment of the RSV F protein is replaced with a linker sequence; and the monomeric and trimeric mutant proteins are both bound by an antibody that specifically recognizes RSV pre-F. The mutant protein can stably remain in a pre-fusion state, can induce the production of specific IgG antibodies and neutralizing antibodies, has excellent immunogenicity, and can be used for the development of RSV vaccines.

An agent including a glycan-specific IgG antibody moiety, a cellular receptor binding moiety which binds to hepatocytes or other degrading cells through asialoglycoprotein (ASGPR) receptors of hepatocytes or other cell receptors which are on the surface degrading cells in a patient or subject, and optionally, a linker moiety connecting the glycan-specific IgG antibody moiety and the cellular receptor binding moiety.

The invention relates to the field of biology, in particular to a duck TRPA1 protein extra-membrane part polyclonal antibody as well as a preparation method and application of the duck TRPA1 protein extra-membrane part polyclonal antibody. The invention provides a duck TRPA1 protein out-of-membrane part polyclonal antibody prepared from TRPA1 recombinant protein and a preparation method of the duck TRPA1 protein out-of-membrane part polyclonal antibody, the titer of the duck TRPA1 protein out-of-membrane part polyclonal antibody is greater than or equal to 1: 256000, and the duck TRPA1 protein out-of-membrane part polyclonal antibody is strong in specificity. The TRPA1 extracellular region (103bp-1051bp) is accurately selected through bioinformatics analysis, so that the expression difficulty caused by a hydrophobic structure of a transmembrane region is avoided, and the target functional epitope of the antibody is ensured; protein aggregation is reduced by utilizing stepped renaturation, and a high-purity antigen is obtained by matching with molecular sieve chromatography; an antigen is coupled with an NHS-active HP column, specific IgG is efficiently captured through a one-step method, and serum impure protein is removed.

The application discloses a bovine parainfluenza virus 3A and 3C type polyepitope antigen peptide, a complex thereof and application. The polyepitope antigen peptides BPMEV-3A and BPMEV-3C have amino acid sequences as shown in SEQ ID NO:1 and SEQ ID NO:3 respectively, and are connected by screening CTL epitopes, HTL epitopes and B cell epitopes from HN and F proteins of BPIV-3A and BPIV-3C strains. Animal immunization tests show that the antigen peptide and the complex thereof can effectively stimulate the body to produce specific IgG antibodies and neutralizing antibodies, induce Th1 type cellular immune response, and effectively eliminate viruses and reduce lung tissue lesions, and show good immunogenicity and protection effect. The application provides an efficient and safe vaccine candidate for prevention and control of BPIV-3, and has a good application prospect.

The present application belongs to the field of biomedical technology, and more particularly relates to the application of Periplaneta americana polypeptide HFDT1 as an immune adjuvant in the preparation of a brucellosis vaccine. The present application uses Brucella OMP10, BP26 and L7 / L12 proteins in combination with HFDT1 to induce mice to produce higher titers of anti-OMP10, BP26 and L7 / L12 protein specific IgG antibodies, and the titers increase with the increase in the number of immunizations, while promoting the body to produce mixed Th1 / Th2 type cellular immune responses and stimulating the proliferation and differentiation of mouse spleen T and B cells, and also facilitating mass production. The Periplaneta americana polypeptide HFDT1 described in the present application is obtained by convenient mass synthesis, and can be used as a novel small molecule immune adjuvant to enhance specific immune responses of the body.

The invention provides polynucleotide for coding an RSV (Respiratory Syndrome Virus) pre-fusion F protein and application of the polynucleotide in an mRNA (Messenger Ribonucleic Acid) vaccine. The sequence of the polynucleotide is as shown in SEQ ID No: 1. Experiments prove that the antigen-specific IgG titer of the polynucleotide, the vaccine and the pharmaceutical composition provided by the invention is 2-4 times that of an unoptimized sequence, so that more efficient expression of target protein in vivo is prompted, and meanwhile, the geometric mean titer value of a neutralizing antibody is also higher than that of the unoptimized sequence, so that good immunogenicity is prompted. The GMT value and the antigen specificity IFN-gamma, IL-5 and IL-17A levels of the neutralizing antibody generated by induction of the RSV mRNA vaccine provided by the invention are obviously higher than those of a control group in the prior art, so that the RSV mRNA vaccine has excellent application prospects.

This invention relates to the field of biomedical technology, specifically disclosing a three-component recombinant subunit vaccine composition for Mycoplasma pneumoniae and its application. The vaccine composition comprises key antigenic proteins of Mycoplasma pneumoniae (MP): P1 protein, P40 / 90 protein, and an E132A attenuated mutant of community-acquired respiratory distress syndrome (CARDS) toxin (CARDS-Mut), optionally combined with Al(OH)3 single adjuvant or Al(OH)3+CPG double adjuvant. The recombinant protein was successfully purified using a prokaryotic expression system, and validated in a mouse model. The vaccine induces high-titer specific IgG antibodies, significantly alleviates lung tissue pathological damage, reduces bacterial load, and inhibits inflammatory factor secretion after challenge, with good safety. This invention solves the problem of high toxicity of CARDS toxin, providing an efficient and safe vaccine strategy for the prevention and control of MP infection.

The invention discloses a coupling protein as well as a preparation method and application thereof. According to the preparation method disclosed by the invention, in-vitro self-coupling of the rotavirus VP8 protein and the norovirus VP1 protein is realized by utilizing a Spatier-Spytag system, the prepared coupled protein can induce a neutralizing antibody with higher titer aiming at the rotavirus, and the immunogenicity of the norovirus VP1 protein is not influenced; the immunized animal / human body can generate a high-titer specific IgG binding antibody, a serum blocking antibody and a neutralizing antibody aiming at the two viruses. The coupling protein has a wide application prospect in vaccines for resisting infant diarrhea viruses (norovirus and rotavirus).

The invention belongs to the technical field of biological medicine, and particularly relates to a manganese-based delivery system with an adjuvant-like function and application of the manganese-based delivery system in vaccine preparation. The invention firstly provides two novel vaccine vectors, namely PMn and YC-coated PMn. PMn is a novel manganese oxide-polyetherimide complex and is obtained by carrying out redox reaction on potassium permanganate and polyetherimide. PMn can be used for loading antigens, loading adjuvants or can be used as adjuvants per se. PMn is loaded into a hollow yeast microcapsule, and a vaccine delivery system which is more stable and has an adjuvant-like function and a slow-release effect is obtained. The vaccine delivery system can be further loaded with protein antigens and / or other molecular adjuvants. Animal experiments prove that the novel sustained-release vaccine delivery system with the adjuvant-like function can be used for remarkably inducing high-level antigen-specific IgG, IgG1 and IgG2a antibodies in animal bodies.

The present invention belongs to the technical field of biomedicine, and specifically relates to a recombinant influenza virus protein, a vaccine, and a preparation method therefor and the use thereof. To overcome the defects of existing influenza vaccines with respect to safety and high toxic side effects, a recombinant influenza virus protein is provided, which has an amino acid sequence as shown in at least one of SEQ ID No. 1 to SEQ ID No. 6. Recombinant hemagglutinin proteins of H1N1 and H3N2 subtypes, and Victoria and Yamagata lineages are expressed and purified by means of an insect baculovirus expression system, and are mixed with an adjuvant to prepare a highly immunogenic recombinant bivalent, trivalent or quadrivalent recombinant influenza virus protein vaccine. The prepared vaccine can induce high levels of specific IgG antibodies and hemagglutination-inhibiting neutralizing antibodies, the addition of adjuvant WGa01 improves the immunogenicity of the vaccine, and the provided vaccine is suitable for people allergic to eggs and has high safety.

The invention belongs to the technical field of biomedicine, and particularly relates to application of periplaneta americana polypeptide and periplaneta americana peptide B serving as an immunologic adjuvant. The amino acid sequence of the periplaneta americana polypeptide and periplaneta americana peptide B is shown as SEQ ID NO.1. According to the invention, influenza virus H1N1RBD protein is combined with periplaneta americana peptide B, mice can be induced to generate an anti-RBD protein specific IgG antibody with higher titer, and the titer of the antibody can be increased along with the increase of immunization times. Meanwhile, the level of T subsets of lymphocytes of a mouse body can be changed, so that the T subsets can resist pathogen invasion to a certain extent. The periplaneta americana polypeptide periplaneta americana peptide B provided by the invention can be conveniently obtained through mass synthesis, can be used as a novel micromolecular immunologic adjuvant, and is beneficial to enhancing the specific immune response of an organism.

The invention provides a novel adjuvant subunit rabies virus vaccine as well as a preparation method and application thereof, the vaccine takes a rabies virus (RABV) glycoprotein extracellular domain prepared by a gene recombination technology as an antigen, and takes a combination of CpG oligodeoxynucleotide and QS21 as an adjuvant. A contrast experiment is carried out on the vaccine, an LNP-mRNA-G-H270P vaccine, a commercial inactivated vaccine and an aluminum adjuvant subunit vaccine, and the result shows that the vaccine can induce a remarkably higher RABV-G specific IgG antibody and virus neutralizing antibody titer, and the humoral immune response is superior to that of other vaccines; meanwhile, moderate and effective Th1 type cell immune response can be induced, so that protective immunity can be supported; 100% protection is achieved in a lethal RABV attack experiment, and the protection effect is equivalent to that of an mRNA vaccine and is remarkably superior to that of an aluminum adjuvant vaccine and a commercial inactivated vaccine. The vaccine provided by the invention has a controllable immune activation mechanism and relatively high safety, avoids the storage risk and excessive inflammatory response of a nucleic acid technology, and is a more reliable and universal choice in the current vaccine technology.

The invention belongs to the technical field of biology, and discloses an application of an outer membrane protein LI0688 of Lawsonia intracellularis in preparation of vaccines and diagnostic reagents, the outer membrane protein LI0688 is a target protein LI0688 after amino acid sequences of a transmembrane region and an intracellular region are removed or a recombinant protein fused by the target protein LI0688 and a His-MBP protein; the outer membrane protein LI0688 can realize soluble expression and purification, can be recognized by rabbit-derived LI positive serum and can induce high-level humoral immune response in a mouse body, and the titer of a specific IgG antibody can reach 1: 819200; the outer membrane protein LI0688 can be simultaneously used as a core antigen of a subunit vaccine and a key component of a high-specificity diagnostic reagent, so that the development cost is greatly reduced. Meanwhile, the invention also discloses a vaccine and a diagnostic kit based on the outer membrane protein LI0688.

The invention discloses application of beta-Hordothionin, an active fragment thereof or a derivative thereof as an intramolecular adjuvant, and particularly relates to a polypeptide derived from beta-Hordothionin, the amino acid sequence of the polypeptide is shown as SEQ ID NO.1, and the polynucleotide sequence of the polypeptide is shown as SEQ ID NO.2. The invention further discloses a preparation method of the beta-Hordothionin and an application of the active fragment or the derivative of the beta-Hordothionin as an intramolecular adjuvant. The polypeptide and a novel coronavirus spike protein receptor binding domain (RBD) are subjected to fusion expression, and the immunogenicity of an antigen can be remarkably enhanced. Experiments show that after a mouse is immunized by the RBD-beta-Hordothionin fusion protein, compared with a pure RBD antigen, the RBD-beta-Hordothionin fusion protein can induce generation of a specific IgG antibody, the titer of the specific IgG antibody is increased by 1000 times, and the fusion protein can be prepared industrially and can be used for improving the immunogenicity of a vaccine antigen.

The invention belongs to the technical field of biological detection, and discloses a food specific IgG antibody detection reagent card, a food specific IgG antibody detection kit, a preparation method and application. The food specific IgG antibody detection reagent card prepared by the preparation method can qualitatively detect and analyze the specific IgG antibody in human serum or fingertip whole blood based on immunochromatography. The kit prepared from the reagent card is used for detecting the food specific IgG antibody, has the characteristics of high detection sensitivity, strong specificity, simplicity in operation, cost saving and the like, and has a great market and a good application prospect.

The invention provides a detection method and a kit for detecting IgM by using a light-activated chemiluminescence double-antigen sandwich method, the purpose of detecting an IgM antibody on a light-activated chemiluminescence platform by using the double-antigen sandwich method is achieved, the problem that the double-antigen sandwich method cannot distinguish IgG and IgM is solved, and the problems that the sensitivity is low and the detection sensitivity is low when the light-activated chemiluminescence indirect method is used for detecting the IgM antibody are solved. The method is easy to be interfered by irrelevant IgM or specific IgG in a sample, needs dilution and is long in time; meanwhile, the problem of interference of specific IgG is solved to a certain extent, and the detection sensitivity and the detection efficiency are improved.

The application belongs to the technical field of biology and discloses a fusion protein S1-linker-Ferritin nanoparticle, wherein the fusion protein S1-linker-Ferritin nanoparticle comprises S1 protein of porcine epidemic diarrhea virus, a ferritin linker and Ferritin protein; the nucleotide sequence of the fusion protein S1-linker-Ferritin nanoparticle is shown in SEQ ID NO. 1, and the amino acid sequence is shown in SEQ ID NO. 2; the fusion protein S1-linker-Ferritin nanoparticle is prepared into a vaccine, and the specific IgG antibody level and the neutralizing antibody level of mice immunized by the vaccine are higher than those of mice immunized by a commercial inactivated vaccine (p<0.01), the number of CD3 + CD4 + , CD3 + CD8 + T cells produced by the mice immunized by the vaccine are higher than those of the mice immunized by the commercial inactivated vaccine. Meanwhile, the application discloses a preparation method of the fusion protein S1-linker-Ferritin nanoparticle and a vaccine containing the fusion protein S1-linker-Ferritin nanoparticle.

The invention discloses a canine anti-cystic hydatid double-antigen recombinant protein subunit vaccine and a preparation method thereof, and relates to the technical field of biological medicines. The canine anti-cystic hydatid double-antigen recombinant protein subunit vaccine takes recombinant proteins rEg 05752 and rEg 09809 as core double antigens, and the recombinant proteins rEg 05752 and rEg 09809 do not have transmembrane regions and signal peptides and contain a plurality of B cell antigen epitopes. After a beagle is immunized, a body can be efficiently induced to generate a specific IgG antibody, the titer of the antibody reaches a peak value 35 days after immunization and still maintains a relatively high level after attack, and meanwhile, Th1 / Th2 type mixed immune response is remarkably activated, so that the levels of cell factors such as IL-2, IFN-gamma, IL-4 and IL-5 are greatly improved. The immune protection effect is remarkable, and a safe and efficient novel technical means is provided for source prevention and control of the cystic echinococcosis.

The invention discloses a bovine parainfluenza virus 3A and 3C type multi-epitope antigen peptide as well as a compound and application thereof. The amino acid sequences of the multi-epitope antigen peptides BPIV-3A and BPIV-3C are respectively shown as SEQ ID NO: 1 and SEQ ID NO: 3, and the multi-epitope antigen peptides are formed by connecting CTL epitopes, HTL epitopes and B cell epitopes screened from HN and F proteins of BPIV-3A and BPIV-3C strains. Animal immune tests show that the antigen peptide and the compound thereof can effectively stimulate a body to generate a specific IgG antibody and a neutralizing antibody, induce immune response of Th1 type cells, effectively eliminate viruses and relieve lung tissue lesions, and show good immunogenicity and protection effect. The invention provides an efficient and safe vaccine candidate for prevention and control of BPIV-3, and has a good application prospect.

The invention discloses an Ad4-55 / Ad7-3 type tetravalent recombinant adenovirus vaccine and an application of the Ad4-55 / Ad7-3 type tetravalent recombinant adenovirus vaccine. The preparation method comprises the following steps: replacing a fifth hypervariable region of an HAdV-4 hexon in an HAdV-4 genome with a second hypervariable region of an HAdV-55 hexon to obtain a recombinant adenovirus Ad4-55; and replacing the first hypervariable region of the HAdV-7 hexon in the HAdV-7 genome with the first hypervariable region of the HAdV-3 hexon, so as to obtain the recombinant adenovirus Ad7-3. And mixing the recombinant adenovirus Ad4-55 and the recombinant adenovirus Ad7-3 to obtain the tetravalent recombinant adenovirus vaccine. Experiments prove that when the tetravalent recombinant adenovirus vaccine prepared by the invention is used for immunizing mice, high-level specific IgG antibodies and neutralizing antibodies can be induced. According to the present invention, the important application value is provided for the prevention and control of HAdV-3, HAdV-7, HAdV-4 and HAdV-55.

The invention relates to a hepatitis A virus (HAV) fusion protein as well as a preparation method and application thereof, prokaryotic expression and purification are carried out based on connection and fusion of main antigen regions of HAV capsid proteins VP1 and VP3, a high-purity HAV-rVP13 fusion protein is obtained, the HAV-rVP13 fusion protein is used as a coating antigen, and an ELISA detection method for an HAV specific IgG antibody is established. By establishing an enterprise calibrator and a quality control product and calibrating by a national HAV specific IgG standard product, the established ELISA detection method can quantitatively determine the concentration of the HAV specific IgG antibody in human plasma / serum, has very high sensitivity and specificity, and can be used for quantitative detection of the HAV IgG antibody in a human plasma / serum sample.

This disclosure is based, at least in part, on an unexpected discovery that the novel nanobodies and variants thereof are able to specifically bind afucosylated or sialylated IgG Fc glycoforms. Glycosylation of the IgG Fc domain is a major determinant of the strength and specificity of antibody effector functions, modulating the binding interactions of the Fc with the diverse family of Fey receptors. These Fc glycan modifications, such as removal of the core fucose residue, are newfound clinical markers for predicting severity of diseases, such as diseases caused by dengue virus (DENV) or SARS-CoV-2. However, it remains challenging to accurately distinguish specific IgG glycoforms without costly and time-intensive methods. The novel glycol-specific nanobodies and variants thereof, as disclosed herein, can be used as rapid clinical diagnostics or prognostics to risk stratify patients with viral and inflammatory diseases, as well as therapeutics for patient treatment.